Financial News
Proactive research analyst says Tiziana Life Sciences "moving forward quite nicely"
February 09, 2023 at 05:24 AM EST
ⓘ This article is third-party content and does not represent the views of this site. We make no guarantees regarding its accuracy or completeness.
Proactive research analyst Robin Davison speaks to Thomas Warner after publishing a 2023 Clinical Outlook for clinical stage biotechnology company Tiziana Life Sciences Ltd (NASDAQ: TLSA). He gives his take on what the market can expect from the business this year, saying that it is now "moving forward quite nicely."
Contact Details
Proactive UK Ltd
Proactive UK Ltd
+44 20 7989 0813
Report this content
If you believe this article contains misleading, harmful, or spam content, please let us know.
Report this articleMore News
View More
Tennant Targets $250M in Robotics Sales as ERP Recovery Gains Traction ↗
September 27, 2026
Equillium Eyes Q4 Phase I Start for Ulcerative Colitis Drug EQ504 ↗
September 27, 2026
Recent Quotes
View More
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.
